Yanyan X. Feng
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.
Journal: The Journal of dermatological treatment
Published: July 15, 2026
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
Journal: The Journal of dermatological treatment
Published: July 06, 2026
Correction: Beyond the boundaries of pigmentation and inflammation: understanding the mechanistic basis of melasma-rosacea comorbidity.
Journal: Frontiers in medicine
Published: May 28, 2026
Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.
Journal: The British journal of dermatology
Published: May 21, 2026
The role and signal pathways of opsin 3 in the skin: from light perception to pathophysiological mechanisms.
Journal: Frontiers in medicine
Published: April 16, 2026
The association between atopic dermatitis and rosacea: a comprehensive review from comorbidities to pathogenic mechanisms.
Journal: Frontiers in immunology
Published: March 24, 2026
Beyond the boundaries of pigmentation and inflammation: understanding the mechanistic basis of melasma-rosacea comorbidity.
Journal: Frontiers in medicine
Published: March 04, 2026
The lipid-inflammation axis in rosacea: mechanistic insights and therapeutic implications.
Journal: Frontiers in immunology
Published: February 28, 2026
Localized Infrared Hyperthermia as an Adjunctive Therapy for Long-Standing Hailey-Hailey Disease: A Case Report.
Journal: Clinical, cosmetic and investigational dermatology
Published: February 17, 2026
SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.
Journal: Frontiers in immunology
Published: February 13, 2026
A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.
Journal: Journal of the American Academy of Dermatology
Published: February 11, 2026
A randomized phase 2 trial of socrodeucitinib in moderate-to-severe plaque psoriasis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 26, 2026
Last Updated: 09/26/2026